Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies

Main Article Content

Eric Simpson
Oregon Health & Science University, Portland, OR, USA

Leon Kircik
Mount Sinai

Andrew Blauvelt
Oregon Health & Science University, Portland, OR, USA

Michael Kuligowski
Incyte Corporation, Wilmington, DE, USA

May Venturanza
Incyte Corporation, Wilmington, DE, USA

Kang Sun
Incyte Corporation, Wilmington, DE, USA

Lawrence Eichenfeld
UC San Diego

Keywords

safety, ruxolitinib, atopic dermatitis, phase 3 study

Abstract

N/A

References

1. Langan SM, et al. Lancet. 2020;396(10247):345-360.

2. Chopra R, et al. Br J Dermatol. 2017;177(5):1316-1321.

3. Vakharia PP, et al. Br J Dermatol. 2018;178(4):925-930.

4. Gooderham MJ, et al. J Cutan Med Surg. 2018;22(suppl 1):10S-16S.

5. Eichenfield LF, et al. J Am Acad Dermatol. 2014;70(2):338-351.

6. Simpson EL, et al. J Am Acad Dermatol. 2017;77(4):623-633.

7. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.

8. Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.

9. Simpson EL, et al. Br J Dermatol. 2020;183(2):242-255.

10. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2020;145(3):877-884.

11. Silverberg JI, et al. JAMA Dermatol. 2020;156(8):863-873

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.66

Article Details

How to Cite
[1]
Simpson, E., Kircik, L. , Blauvelt, A. , Kuligowski, M., Venturanza, M., Sun, K. and Eichenfeld, L. 2021. Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s66. DOI:https://doi.org/10.25251/skin.5.supp.66.
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>